María Célica Ysrraelit

Dr. María Célica Ysrraelit

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2009 in Brain
Verified
Journal Article
Closed access
PDF file
JCJorge Correale
Jorge Correale
MYMaría Célica Ysrraelit
María Célica Ysrraelit
MGMaría Inés Gaitán
María Inés Gaitán
Although Vitamin D is best known as a modulator of calcium homeostasis, it also has immune modulating potential. A protective effect of Vitamin D on multiple sclerosis is supported by the reduced risk associated with sun exposure and use of Vitamin D supplements. Moreover, high circulating levels of Vitamin D have been associated with lower risk of multiple sclerosis. In this study, we measured 1,25 (OH)2 Vitamin D and 25 (OH) Vitamin D levels in multiple sclerosis patients separated into different clinical subgroups according to disease status. In addition, direct effects of 1,25 (OH)2 Vitamin D on ex vivo CD4+ T cells and myelin-peptide specific T cell lines were investigated to gain more insight into putative regulatory mechanisms in the disease pathogenesis. One hundred and thirty-two Hispanic patients with clinically definite multiple sclerosis were studied, 58 with relapsing remitting multiple sclerosis during remission, 34 during relapse and 40 primary progressive multiple sclerosis cases. Sixty healthy individuals matched with respect to place of residence, race/ethnicity, age and gender served as controls. Levels of 25(OH)D3 and 1,25(OH)2D3, measured by ELISA were significantly lower in relapsing–remitting patients than in controls. In addition, levels in patients suffering relapse were lower than during remissions. In contrast, primary progressive patients showed similar values to controls. Proliferation of both freshly isolated CD4+ T cells and MBP-specific T cells was significantly inhibited by 1,25(OH)2D3. Moreover, activated Vitamin D enhanced the development of IL-10 producing cells, and reduced the number of IL-6 and IL-17 secreting cells. Notably, Vitamin D receptor expression was induced by 1,25(OH)2D3 in both activated and resting cells. Interestingly, T cells were able to metabolize 25(OH)D3 into biologically active 1,25(OH)2D3, since T cells express α1-hydroxylase constitutively. Finally, 1,25(OH)2D3 also increased the expression and biological activity of indoleamine 2,3-dioxygenase, mediating significant increase in the number of CD4+CD25+ T regulatory cells. Collectively, these data suggest that 1,25(OH)2D3 plays an important role in T cell homeostasis during the course of multiple sclerosis, thus making correction of its deficiency may be useful during treatment of the disease.

29 October 2016 in Brain
Verified
Journal Article
Closed access
PDF file
JCJorge Correale
Jorge Correale
MGMaría I. Gaitán
María I. Gaitán
MYMaría Célica Ysrraelit
María Célica Ysrraelit
MFMarcela P. Fiol
Marcela P. Fiol
During the past decades, better understanding of relapsing-remitting multiple sclerosis disease mechanisms have led to the development of several disease-modifying therapies, reducing relapse rates and severity, through immune system modulation or suppression. In contrast, current therapeutic options for progressive multiple sclerosis remain comparatively disappointing and challenging. One possible explanation is a lack of understanding of pathogenic mechanisms driving progressive multiple sclerosis. Furthermore, diagnosis is usually retrospective, based on history of gradual neurological worsening with or without occasional relapses, minor remissions or plateaus. In addition, imaging methods as well as biomarkers are not well established. Magnetic resonance imaging studies in progressive multiple sclerosis show decreased blood–brain barrier permeability, probably reflecting compartmentalization of inflammation behind a relatively intact blood–brain barrier. Interestingly, a spectrum of inflammatory cell types infiltrates the leptomeninges during subpial cortical demyelination. Indeed, recent magnetic resonance imaging studies show leptomeningeal contrast enhancement in subjects with progressive multiple sclerosis, possibly representing an in vivo marker of inflammation associated to subpial demyelination. Treatments for progressive disease depend on underlying mechanisms causing central nervous system damage. Immunity sheltered behind an intact blood–brain barrier, energy failure, and membrane channel dysfunction may be key processes in progressive disease. Interfering with these mechanisms may provide neuroprotection and prevent disability progression, while potentially restoring activity and conduction along damaged axons by repairing myelin. Although most previous clinical trials in progressive multiple sclerosis have yielded disappointing results, important lessons have been learnt, improving the design of novel ones. This review discusses mechanisms involved in progressive multiple sclerosis, correlations between histopathology and magnetic resonance imaging studies, along with possible new therapeutic approaches. * Abbreviations : EAE : experimental autoimmune encephalomyelitis EBV : Epstein-Barr virus EDSS : Expanded Disability Status Scale FLAIR : fluid-attenuated inversion recovery IFN : interferon IL : interleukin MTR : magnetization transfer ratio NAA : N -acetylaspartate NAWM : normal-appearing white matter PPMS : primary progressive multiple sclerosis ROS : reactive oxygen species RRMS : relapsing remitting multiple sclerosis SPMS : secondary progressive multiple sclerosis TNF-α : tumor necrosis factor-α

1 September 2015 in Cell
Verified
Journal Article
Closed access
MFMauricio F. Farez
Mauricio F. Farez
IMIvan D. Mascanfroni
Ivan D. Mascanfroni
SMSantiago P. Méndez-Huergo
Santiago P. Méndez-Huergo
AYAda Yeste
Ada Yeste
GMGopal Murugaiyan
Gopal Murugaiyan
JCJorge Correale
Jorge Correale

20 February 2019 in Biomedicines
Verified
Journal Article
Open access
PDF file
JCJorge Correale
Jorge Correale
MMMariano Marrodan
Mariano Marrodan
MYMaría Célica Ysrraelit
María Célica Ysrraelit
Multiple Sclerosis (MS) is a major cause of neurological disability, which increases predominantly during disease progression as a result of cortical and grey matter structures involvement. The gradual accumulation of disability characteristic of the disease seems to also result from a different set of mechanisms, including in particular immune reactions confined to the Central Nervous System such as: (a) B-cell dysregulation, (b) CD8+ T cells causing demyelination or axonal/neuronal damage, and (c) microglial cell activation associated with neuritic transection found in cortical demyelinating lesions. Other potential drivers of neurodegeneration are generation of oxygen and nitrogen reactive species, and mitochondrial damage, inducing impaired energy production, and intra-axonal accumulation of Ca2+, which in turn activates a variety of catabolic enzymes ultimately leading to progressive proteolytic degradation of cytoskeleton proteins. Loss of axon energy provided by oligodendrocytes determines further axonal degeneration and neuronal loss. Clearly, these different mechanisms are not mutually exclusive and could act in combination. Given the multifactorial pathophysiology of progressive MS, many potential therapeutic targets could be investigated in the future. This remains however, an objective that has yet to be undertaken.

15 October 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JCJorge Correale
Jorge Correale
MYMaría Célica Ysrraelit
María Célica Ysrraelit
MGMaría I Gaitán
María I Gaitán
Vitamin D3 is best known as a calcium homeostasis modulator; however, it also has immune-modulating potential. In this study, we demonstrated that immunomodulatory effects of vitamin D3 are significantly stronger in females than in males in multiple sclerosis patients, as well as in healthy subjects. Inhibition of self-reactive T cell proliferation and reduction in IFN-γ– and IL-17–secreting cell numbers were considerably greater in females. Furthermore, the increase in IL-10–secreting and CD4+CD25+FoxP3+ regulatory T cell numbers were also greater in females. In parallel with these findings, female subjects had fewer CYP24A1 transcripts encoding the 1,25-dihydroxyvitamin D3-inactivating enzyme, as well as greater binding and internalization of vitamin D3-binding protein, a transporter for vitamin D3 and its metabolites. These gender-based disparities lead to the accumulation of vitamin D3 and its metabolites in target cells from female subjects and result in a more potent anti-inflammatory effect. Interestingly, 17-β estradiol reproduced these effects on self-reactive T cells and macrophages from male subjects, suggesting a functional synergy between 1,25-dihydroxyvitamin D3 and 17-β estradiol, mediated through estrogen receptor α. Collectively, these results demonstrate estrogen-promoted differences in vitamin D3 metabolism, suggesting a greater protective effect of vitamin D3-based therapeutic strategies in women.

3 October 2012 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JCJorge Correale
Jorge Correale
MFMauricio F. Farez
Mauricio F. Farez
MYMaría Célica Ysrraelit
María Célica Ysrraelit